F10 and Alzheimer disease: After considering the pros and cons of the available DOACs, which come from basic and preclinical research, clinical observer studies, data bases on bleeding risk, and availability of antidote, the thrombin inhibitor dabigatran and the FXa-inhibitors apixaban and rivaroxaban are on the list of preferential drugs for a clinical study in AD.